Novartis AG stock (CH0012005267): Q1 earnings beat and shares up 1%

Novartis AG reported Q1 EPS of $1.99 on April 27, beating expectations, with shares rising 1.06% to $149.73 on NYSE as of May 13, 2026.

Novartis AG (NYSE:NVS), the Swiss pharmaceutical giant, released its first-quarter earnings on April 27, 2026, posting earnings per share of $1.99, according to MarketBeat as of 05/13/2026. The stock advanced 1.06% to close at $149.73 on May 13, 2026, on the NYSE, reflecting positive market reception amid ongoing volatility in biotech.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novartis AG
• Sector/industry: Pharmaceuticals
• Headquarters/country: Basel, Switzerland
• Core markets: Global, with strong US presence
• Key revenue drivers: Innovative medicines, generics
• Home exchange/listing venue: NYSE (NVS), SIX Swiss Exchange
• Trading currency: USD on NYSE

Novartis AG: core business model

Novartis AG focuses on researching, developing, manufacturing, and commercializing prescription medicines and healthcare products worldwide. Headquartered in Basel, Switzerland, the company operates through its Innovative Medicines and Sandoz divisions, targeting areas like cardiovascular, immunology, neuroscience, and oncology. This diversified portfolio supports stable revenue streams for US investors tracking global pharma leaders listed on NYSE.

The business model emphasizes innovation, with heavy R&D investment yielding blockbuster drugs. Novartis maintains a strong US market exposure, where it generates significant sales from therapies addressing prevalent health issues like gene therapies and rare diseases.

Main revenue and product drivers for Novartis AG

Key products include Entresto for heart failure, Cosentyx for immunology, and Kisqali in oncology, driving core revenue growth. In Q1 2026, operational performance underpinned the $1.99 EPS figure reported on April 27, per MarketBeat as of 05/13/2026. Sandoz generics further bolster margins amid patent cliffs.

Novartis' US relevance stems from its NYSE listing and substantial revenue from American patients, positioning it as a staple for portfolios seeking defensive healthcare exposure with dividend yields around 2.06% as of May 2026 data from MarketBeat.

Industry trends and competitive position

The global pharma sector faces pricing pressures and biosimilar competition, yet Novartis holds a competitive edge through its pipeline of over 30 new molecular entities in development. Market cap stood at $285.70 billion as of May 13, 2026, ranking it among top global players, per MarketBeat.

Why Novartis AG matters for US investors

Listed on NYSE under NVS, Novartis offers US investors access to a diversified Swiss pharma powerhouse with deep US market penetration. Its 52-week range of $104.93 to $170.46 as of May 13, 2026, highlights volatility opportunities in a sector tied to US healthcare spending and FDA approvals.

Conclusion

Novartis AG's Q1 earnings of $1.99 EPS on April 27, 2026, and subsequent 1.06% stock rise to $149.73 underscore resilient operations in a competitive pharma landscape. With a market cap over $285 billion and a 2.06% dividend yield, it remains a key watch for US investors balancing growth and stability. Ongoing pipeline developments will shape future performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.